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Abstract:  Three  simple  spectrophotometric  and  atomic  absorption  spectrometric  methods  are  developed  and  validated  for  the 
determination of moxifloxacin HCl in pure form and in pharmaceutical formulations. Method (A) is a kinetic method based on the 
oxidation of moxifloxacin HCl by Fe3+ ion in the presence of 1,10 o-phenanthroline (o-phen). Method (B) describes spectrophotometric 
procedures for determination of moxifloxacin HCl based on its ability to reduce Fe (III) to Fe (II), which was rapidly converted to the 
corresponding stable coloured complex after reacting with 2,2′ bipyridyl (bipy). The formation of the tris-complex formed in both 
methods (A) and (B) were carefully studied and their absorbance were measured at 510 and 520 nm respectively. Method (C) is based 
on the formation of ion- pair associated between the drug and bismuth (III) tetraiodide in acidic medium to form orange—red ion- pair 
associates. This associate can be quantitatively determined by three different procedures. The formed precipitate is either filtered off, 
dissolved in acetone and quantified spectrophotometrically at 462 nm (Procedure 1), or decomposed by hydrochloric acid, and the 
bismuth content is determined by direct atomic absorption spectrometric (Procedure 2). Also the residual unreacted metal complex 
in the filtrate is determined through its metal content using indirect atomic absorption spectrometric technique (Procedure 3). All the 
proposed methods were validated according to the International Conference on Harmonization (ICH) guidelines, the three proposed 
methods permit the determination of moxifloxacin HCl in the range of (0.8–6, 0.8–4) for methods A and B, (16–96, 16–96 and 16–72) 
for procedures 1–3 in method C. The limits of detection and quantitation were calculated, the precision of the methods were satisfactory; 
the values of relative standard deviations did not exceed 2%. The proposed methods were successfully applied to determine the drug in 
its pharmaceutical formulations without interference from the common excipients. The results obtained by the proposed methods were 
comparable with those obtained by the reference method.
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Introduction
Moxifloxacin  [1-Cyclopropyl-b-fluoro-1,4-dihydro-
8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo 
[3,4–6] pyridine-6-yl]-4-oxo-3-quinoline carboxylic 
acid]1  is  a  broad-spectrum  antibiotic  that  is  active 
against both Gram-positive and Gram-negative bacte-
ria.2 The bactericidal activity of the drug is mediated 
by the inhibition of DNA gyrase (topoisomerase II) 
and topoisomerase IV, essential enzymes involved in 
bacterial DNA replication, transcription, repair and 
recombination.  Moxifloxacin  is  prescribed  for  the 
bacterial infections of the respiratory tract including 
sinusitis, community acquired pneumonia and acute 
exacerbations of chronic bronchitis.3
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Few methods were reviewed in the literature for the 
analysis  of  moxifloxacin  HCl.  Spectrophotometric,4,5 
spectrofluorimetric,6 liquid chromatographic,7–10 TLC,11 
HPLC,12–16 Capillary electrophoresis,17,18 polarographic,19 
and  voltammetric20,21  procedures  were  applied  for  its 
determination.
Still, there is a need for simple methods to   compete 
with  the  new,  advancement  and  automated  ones. 
Therefore, the present study aims to use spectropho-
tometric and atomic absorption spectrometric (AAS) 
techniques  for  the  determination  of  moxifloxacin 
HCl in pure form and pharmaceutical formulations. 
  Methods A and B are based on the oxidation of the 
drug by Fe3+ in the presence of (o-phen) or (bipy) and 
then the tris-complex formed was measured at 510 
and 520 nm respectively. While method C based on 
the precipitation of the ion pair of the drug with bis-
muth (III) tetraiodide and quantifying it via the formed 
precipitate of the metal ion present in the supernatant 
solution using (AAS). The proposed methods were 
successfully applied to the determination of moxi-
floxacin HCl in tablet dosage forms without interfer-
ence of any additives or excipients.
experimental Apparatus
A  Shimadzu  recording  spectrometer  UV-1800 
equipped with 10 mm two matched quartz cells was 
used for spectrophotometric measurements. Atomic 
absorption  measurements  were  carried  out  using 
  Shimadzu  atomic  absorption  spectrometric  device 
model AA-640-13 at 223 nm analysis wavelength, 
lamp current 5 mA, slit width 0.38 nm, burner height 
5 mm, burner slot, flame 10 cm air-C2H2, support gas 
flow 10 I min−1, fuel gas flow 2.6 I min−1 and absorp-
tion sensitivity of 0.6 ppm.
Materials and Reagents
All materials used were of analytical reagent grade, 
water  was  always  doubly  distilled.  Pure  sample 
  moxifloxacin  HCl  was  kindly  provided  by  Sabaa 
International  Company  for  pharmaceuticals  and 
chemical industries S.A.E.
The Standard stock solution (0.8 mg ml−1) in water 
were prepared by dissolving 80 mg of pure drug in 
convenient amount of double distilled water in 100 ml 
volumetric flask followed by dilution to the mark with 
the same solvent, it is stable for at least 2 weeks if it 
was stored in a cool (,25 °C).
Pharmaceutical preparations: Moxifloxacin tablets 
(400 mg moxifloxacin HCl/tablet) were provided by 
Sabaa  International  Company  for  pharmaceuticals 
and chemical industries S.A.E. (Batch No. 09002).
Iron (III)-o-phenanthrolin22 was prepared by mix-
ing  0.198  g  of  1,10  phenanthroline  monohydrate 
(Aldrich Chem. Co. Miluwakee, USA), 2 ml 1 M HCl and   
0.16  g  ferric  ammonium  sulphate  dodecahydrate 
(Aldrich,  Germany)  before  dilution  with  double 
distilled  water  to  100  ml  in  a  calibrated  flask. 
Iron (III) – bipyridyl22 was prepared by mixing 0.16 g 
of 2,2′ bipyridyl (Sigma Chem. Co. Miluwakee, USA) 
with 2 ml 1 M HCl and 0.16 g ferric ammonium sul-
phate dodecahydrate, before dilution with double dis-
tilled water to 100 ml in a calibrated flask.
Standard bismuth (III) solution, 0.01 M, was pre-
pared by dissolving 0.1 g of Bi(NO3). 5H2O (Merck) 
in 2.5 ml of HNO3 and adding double distilled water 
to  25  ml  and  standardized  complexometrically.23 Development and validation of spectrophotometric, AAS, kinetic methods for determination of moxifloxacin
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Potassium iodide solution, 0.5 M, was prepared by 
dissolving 8.28 g of KI (Merck) in 100 ml of double 
distilled water. 2% HNO3 solution was prepared in 
double distilled water. 0.8 × 10−3 M solutions of bis-
muth (III) nitrate and drug were prepared.
General procedures
Methods A and B
(0.8–6) (0.8–4) µgml−1 aliquots of the standard solutions 
for methods A and B respectively were transferred to 
a series of 10 ml calibrated flasks. 4 ml of Fe3+-o-phen 
(method A) or 3.5 ml of Fe3+-bipy (method B) were 
added, then heating on a boiling water bath for 35, 
30 minutes for methods A and B respectively. Mix-
ture was cooled to room temperature (25 °C ± 1 °C), 
completed to volume with double distilled water. The 
coloured  complexes  formed  were  measured  at  510 
and 520 nm against a reagent blank treated similarly 
according to methods A and B respectively.
Procedures for the kinetic method
Aliquots of (0.8–6 µgml−1) of moxifloxacin HCl were 
assayed as in the general procedure for method A at 
different times (10, 25, 40, 60 minutes) in a boiling 
water bath.
Method C
Procedure 1
To a series of 10 ml volumetric flasks, 0.7 ml of 0.01 
M bismuth (III) nitrate solution was added followed 
by 0.8 ml of 0.5 M potassium iodide solution with 
  continuous mixing. Accurately measured aliquots of 
the drug (Table 1) were then added followed by 0.7 ml 
of 2% HNO3. The solution was shaken to coagulate 
the precipitate then completed to volume with double 
distilled water, mixed well, and filtered. The precipi-
tate obtained was washed with 2 ml 2% HNO3, com-
pletely dried in a vacuum desiccant, then dissolved 
quantitatively in acetone and the volume was made 
up to 10 ml in calibrated flask. The   absorbance was 
measured  at  462  nm  against  an  appropriate  blank 
  prepared simultaneously.
Procedure 2
The  precipitate  in  procedure  1  was  quantitatively 
decomposed into 10 ml volumetric flasks using 1 ml 
concentrated HCl, the mixture was completed to 10 ml 
with double distilled water and aspirated directly in the 
atomic absorption spectrometer, absorption was mea-
sured at 2230 A° against an appropriate blank prepared 
simultaneously. Concentration of the consumed bis-
muth was calculated from a calibration graph of stan-
dard Bi(NO3) solution or using regression equation.
Procedure 3
The filtrate of procedure 1 were transferred to 25 ml 
volumetric flask, diluted to volume with double dis-
tilled  water,  absorbance  was  then  measured  using 
atomic  absorption  spectrometer  at  2230 A°  against 
an appropriate blank prepared simultaneously, excess 
Table 1. Spectral data for determination of moxifloxacin HCl using methods (A, B and C).
Items Method A Method B Method c
procedure 1 procedure 2 procedure 3
Linearity range  
(µgml–1)
0.8–6 0.8–4 16–96 16–96 16–72
Apparent molar absorpitivity*  
(L mol–1 cm–1)
6.61 × 104 8.5 × 104 4.5 × 103 1.2 × 106 1.2 × 106
Sandell’s sensitivity**  
(µg/cm2/0.001 Abs. unit)
0.0151 0.0196 1.03 × 10−3 0.289 0.287
Intercept (a)*** 0.10939 0.0266 0.08153 0.6215 0.6071
Slope (b)  
Correlation coefficient (r)
0.11755  
0.9998
0.1862  
0.9998
0.0083174  
0.9999
2.879  
0.9999
2.8526  
0.9998
Variance 0.74 0.50 0.57 0.69 0.73
Detection limit (µgml–1) 0.076 0.21 1.41 1.42 1.43
Quantification limit (µgml–1) 0.254 0.69 4.67 4.74 4.78
notes: *Calculated on the basis of the molecular weight of the drug; **limit of determination as the weight in µg per ml of solution, which corresponds to 
an absorbance of A = 0.001 measured in a cuvette of cross-sectional area 1 cm2 and l = 1 cm; ***A = bX + a, Where A is the absorbance, X is concentration 
in µgml−1, a is intercept, b is slope.Abdellaziz and hosny
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Figure 1. Reactions of moxifloxacin HCl with 1,10 (o-phen) and 2, 2′(bipy).
concentration was then determined from a calibration 
graph of standard Bi(NO3) solution or using regression 
equation. The concentration of the drug was then cal-
culated where 15.27 µgml−1 Bi (III) ≡ 16 µgml−1 drug.
Procedure for dosage forms
An  accurately  weighed  quantity  of  the  pulverized 
tablets equivalent to 80 mg of the studied drug was 
extracted  with  double  distilled  water.  Mixture  was 
  filtered through a filter paper and washed with water, 
the filtrate and washing were collected in a 100 ml stan-
dard flask and diluted to volume with double   distilled 
water. Aliquots of this solution were transferred in a 
series of 10 ml volumetric flasks, and the analysis was 
completed as previously mentioned using methods A, 
B and C by using standard addition technique.
Results and Discussion
Methods A and B
1,10 (o-phen) and 2,2′(bipy) are common reagents 
for ferrous ion as their red color chelate [Fe(phen)3]2+, 
[Fe(bip)3]2+  complexes  remained  stable  for  weeks. 
These methods were based on the reducing properties 
of the drug, it reduces Fe(III) to Fe(II) which was con-
verted rapidly to the corresponding stable coloured 
reagent Fe(II) complex. (Fig. 1).
Absorption  spectra  were  measured  at  510  and 
520 nm for 1,10 (o-phen) and 2, 2′(bipy) respectively 
(Figs. 2 and 3).
Optimum conditions affecting the reaction were 
studied:
1. Effect of reagent volume: It was found that 4 and 
3.5 ml of 1,10 (o-phen) and 2,2′(bipy) respectively 
were suitable to give optimum results with moxi-
floxacin HCl.
2.  Effect of temperature and heating time: At   ambient 
temperature (25 °C ± 2 °C), the reaction was very   
slow, when temperature increases, the reaction was 
faster until it reach the   maximum absorbance in a 
  boiling water bath (100 °C).   Heating for 35–30   minute 
in a boiling water bath gave the maximum absor-
bance for methods A and B respectively.
3. Effect of solvent: Different solvents such as water, 
ethanol and isopropyl alcohol were tried in dilution, 
water was found to be the most suitable solvent.
After diluting the reaction solution mixture, it was 
found that the absorbance of the chromogen formed in 
method A and B are remained stable for at least 2 hours. 
This allowed the processing of large batches of samples, 
and their comfortable measurements with convenience 
so the methods will be more applicable for large number 
of samples, calibration graphs obtained were found to be 
linear over concentration ranges stated in (Table 1).The 
linearity was evaluated by the relative standard devia-
tion of the slope,24 standard error, variance, Sandell’s 
sensitivity were also calculated (Tables 1 and 2).
results and discussion of kinetic 
spectrophotometric procedure  
for determination of moxifloxacin  
with 1,10 (o-phen) and FeCl3
The rate of the reaction was found to be dependent 
on the drug concentration, the rate was followed at 
100 ° C  with  various  concentrations  of  the  studied 
drug in the range of (0.8–6) µgml−1 (Fig. 4).
It is clear that the rate increases as the studied drug 
concentration increases, indicating that the reaction 
rate obeys the following equation:
  Rate = K′ [drug]n  (1)Development and validation of spectrophotometric, AAS, kinetic methods for determination of moxifloxacin
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result in a pseudo-first order reaction with respect to 
its concentration. However, the rate will be directly 
proportional to drug concentration in a pseudo-first 
order rate equation as follows:
  Rate = K′ [drug]  (3)
where K′ is the pseudo-first order constant.   Equation (3) 
was the basis for several experiments, which were run 
to obtain drug concentration using the rate data. Rate 
constant, constant concentration and fixed-time.26,27 
The  most  suitable  analytical  method  was  selected 
taking into account the applicability, the sensitivity, 
the correlation   coefficient (r) and the intercept.
rate-constant method
Graphs of log (absorbance) versus time for the stud-
ied drug concentrations in the range (1.826 × 10−6 
to 1.370 × 10−5 M) was plotted and appeared to be 
rectilinear.  Pseudo-first  order  rate  constants  corre-
sponding to different drug concentrations (C) were 
calculated from the slopes multiplied by −2.303 and 
are presented in (Table 4), (Fig. 5).
Regression of (C ) versus K′ gave the equation:
K′ = 1.2999 × 10−5 + 0.015532 C ( r = 0.9619)  (4)
The  value  (r)  indicates  poor  linearity,  which  is 
probably due to inconsistency of K′ as a result of 
slight changes due to the elevated temperature of the 
reaction.
Fixed-concentration method
Reaction rates were determined for different concen-
trations in the range 1.826 × 10−6 to 1.370 × 10−5 M 
of  moxifloxacin  HCl.  A  pre-selected  value  of  the 
absorbance was fixed and the time was measured in 
seconds. The reciprocal of time (ie, 1/t) versus the 
initial  concentration  of  the  studied  drug  (Table  5) 
was   plotted. The following equations for calibration 
graphs were worked out by linear regression:
1/t = 5.204 × 10−7 + 8.0241 × 10−3 C ( r = 0.99838)
    (5)
The range of the concentration of the studied drug 
giving the most acceptable calibration graph with the 
above equations was very limited, which could be 
disadvantage.
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Figure 2. Absorption spectra of the complex formed through reaction of 
4.8 µgml−1 Moxifloxacin HCl with 1,10 phenanthrolin and FeCl3.
0.000
420.00 450.00 500.00
nm
A
b
s
.
550.00 600.00
0.200
0.400
1
0.600
2
Figure 3. Absorption spectra of the complex formed through reaction of 
1.8 µgml−1 Moxifloxacin HCl with 2,2′ bipyridyl and FeCl3.
where K′ is the pseudo-order constant of the reaction and 
n is the order of the reaction. The rate of the reaction may 
be estimated by the variable-time method   measurement25 
as ∆A/∆t, where A is the absorbance and t is the time in 
seconds. Taking logarithms of rates and concentration 
(Table 3) equation (1) is transformed into:
  log (rate) = log ∆A/∆t = log K′ + n log [drug]  (2)
Regression of log (rate) versus log (drug) gave the 
regression equation:
log (rate) = −0.750 + 0.541 log C ( r = 0.969), 
  K′ = 5.623 S−1
Hence the reaction is first order (n ≈ 1) with respect to 
drug concentration.
evaluation of the kinetic methods
The quantitative of the studied drug under the opti-
mized experimental conditions outlined above, would Abdellaziz and hosny
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Table 3. Logarithms of the rates for different concentrations 
of moxifloxacin hydrochloride at constant concentration of 
1,10 (o-phen) and FeCl3.
Log (rate), log ∆A/∆t Log (drug) (M)
−3.82 −5.74
−3.64 −5.26
−3.59 −5.14
−3.38 −4.93
−3.35 −4.86
Table 2. Determination of moxifloxacin HCl using methods A and B.
Method A Method B
Taken (μgml-1) Recovery % Taken (μgml-1) Recovery %
0.8 99.54 0.8 99.62
2.4 99.46 2 100.62
3.2 101.18 2.8 100.58
5.2 99.07 3.6 98.96
6 100.47 4 100.61
Mean* ± Standard deviation (P = 0.05) 99.94 ± 0.8610 100.01 ± 0.7074
n 5 5
Variance 0.7413 0.5004
Standard error 0.3850 0.316
note: *Mean of three different experiments.
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Figure  4.  Absorbance  versus  time  graphs  for  the  reaction  between 
moxifloxacin  HCl  and  1,10  phenanthrolin  showing  the  dependance 
of the reaction on drug concentration (1) 1.826 × 10−6; (2) 5.48 × 10−6;   
(3) 7.307 × 10−6; (4) 1.187 × 10−5; (5) 1.370 × 10−5.
Fixed time method
Reaction rates were determined for different concen-
tration of the studied drug, at a pre-selected fixed time, 
which  was  accurately  determined,  the  absorbance 
was measured. Calibration graph of the absorbance 
versus initial concentration of the moxifloxacin HCl 
was obtained at fixed times of 10, 25, 35 and 40 min 
with the calibration equation shown in (Table 6). It is 
clear that, the most acceptable values of the correla-
tion coefficient and more reaction products (indicated 
by higher absorbance readings were obtained for a 
fixed time of 35 min, which was, therefore chosen as 
the most suitable time interval for measurements.
After  optimizing  the  reaction  conditions,  the 
fixed time method was applied to the determination 
of moxifloxacin hydrochloride in pure form and in 
pharmaceutical formulations over the concentration 
range of (0.8–6 µgml−1). Analysis of the date gives 
the   following regression equation:
  A = 0.10939 + 0.11755 C   (r = 0.9998)  (6)
Method C
Formation of ion- pairs between many nitrogenous 
drugs and metal complexes found wide applications in 
the field of drug analysis applying colourimetric and 
(AAS) methods as well as ion-selective electrodes.28–37 
In this work the investigated drug react with bismuth 
(III) tetraiodide to form stable ion- pair complex, this 
interaction and subsequent formation of the ion- pair 
occur in acidic medium via the two centers of tertiary 
amino group of the drug, one of them was formed due 
to the addition of acid) and two molecules of bismuth 
(III) tetraiodide. Being insoluble in aqueous solution, 
this ion- pair complex might be possibly isolated by 
direct filtration or extraction into organic solvents and 
assayed accurately without interference from excess 
unreacted metal complex.
Bismuth (III) tetraiodide complex was used as a 
reagent for the determination of some nitrogenous 
compounds.35–37  On  mixing  aqueous  solutions  of 
bismuth (III) tetraiodide complex and drug in acidic 
medium, a reddish orange precipitate instantaneously Development and validation of spectrophotometric, AAS, kinetic methods for determination of moxifloxacin
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owing  to  possible  errors  during  isolation  steps, 
automation of the methods enhance the overall ana-
lytical progress of the proposed procedure, making 
them more suitable for routine quality control analy-
sis of the studied drug.
The  different  experimental  parameters  affecting 
the formation of the ion- pair complex were studied 
to determine the optimum conditions for the assay 
procedure:
1. Effect of reagents volume: It was found that 0.7 ml 
of 0.01 M bismuth nitrate and 0.8 ml of 0.5 M 
potassium iodide were required to obtain the max-
imum precipitation of the drug as its ion- pair.
2. Effect of acid concentration: The choice of a suit-
able pH value at which the ion associate exhibit 
the lowest solubility (at 25 °C) is of prime impor-
tance in the use of such compounds in quantita-
tive analysis. To determine this pH value, 0.05 M 
of KOH or 2% HNO3 was used to adjust the pH 
of the solution, from the obtained results, it was 
observed that at pH . 3, there is a decrease in the 
precipitation yield with increase in pH, probably 
because of precipitation of bismuth as a hydroxo-
species. The absorbance was maximum at pH 1.7 
which was achieved by using 0.7 ml 2% HNO3.
Generally  the  formation  of  the  ion-  pair  was 
rapid and the colour production was still stable for 
Table 4. Values of K′ calculated from slope of log A vs.   
t graphs multiplied by −2.303 for different concentrations 
of moxifloxacin hydrochloride and constant concentration 
of reagent.
K′ (s-1) (M)
−7.5943 × 10−4 1.826 × 10−6
−4.1338 × 10−4 5.480 × 10−6
−3.396 × 10−4 7.307 × 10−6
−1.5966 × 10−5 1.187 × 10−5
−9.562 × 10−5 1.370 × 10−5
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Figure 5. Values of K′ calculated from slopes of different log A vs. t graph 
multiplied by −2.303 for different concentrations of drug at constant con-
centration of reagent.
Table  5.  Values  of  reciprocal  of  time  taken  at  fixed 
absorbance for different rates of variable concentration of 
moxifloxacin hydrochloride.
1/t (s–1) (M)
1.66 × 10−3 1.370 × 10−5
1.388 × 10−3 1.187 × 10−5
8.547 × 10−4 7.307 × 10−6
Table 6. Calibration equations for moxifloxacin hydrochlo-
ride at different fixed time over the range of 1.826 × 10−6 
–1.370 × 10−5 M in presence of constant concentration of 
reagent.
Time  
(min)
calibration equation correlation  
coefficient (r)
10 A = 0.03486 + 0.0813 C 0.9818
25 A = 0.1295 + 0.1136 C 0.9959
35 A = 0.10939 + 0.11755 C 0.9998
40 A = 0.0934 + 0.1192 C 0.9986
appeared that is attributed to the ion- pair formed in 
the reaction. This precipitate was filtered off and the 
residual unreacted bismuth (III) tetraiodide complex 
in the filtrate was analyzed using atomic absorption 
spectrometric technique. On the other hand the pre-
cipitate could be dissolved in acetone and analyzed 
spectrophotometrically at its peak absorption maxi-
mum at 462 nm (Fig. 6) or dissolved in HCl for atomic 
absorption spectrometric estimation.
Extraction of the formed ion- pair with different 
solvents was also studied, low polarity solvents such 
as chloroform and dichloromethane were inefficient 
due to insolubility of the ion- pair in such solvents, 
solvents  with  increase  polarity  such  as  n-butanol, 
acetone, and isobutyl methyl ketone lacked selectivity 
and did not differentiate between the ion- pair formed 
and the residual unreacted bismuth (III) tetraiodide in 
the aqueous phase, therefore filtration was necessary 
to separate the formed ion- pair.
Determination of the residual non-consumed bis-
muth (III) tetraiodide complex in the filtrate had the 
advantages of being rapid, simpler, precise than the 
direct dissolution of the isolated ion- pair precipitate Abdellaziz and hosny
74  Analytical Chemistry Insights 2011:6
more  than  24  hour. The  more  favorable  sequence 
addition is bismuth (III)-KI- drug for the highest and 
  completion- ion- pair formation. The linearity was 
evaluated by the relative standard deviation of the 
slope, standard error, variance, Sandell’s sensitivity.
(Tables 1 and 7).
Composition of the ion- pair associates
The composition of the ion- pair associates was estab-
lished by molar ratio method.38 using equimolar solu-
tions of the drug and reagent (0.8 × 10−3), the results 
obtained indicate that the composition of the associ-
ates was (1:2) drug to reagent. According to this ratio 
it was found that 15.27 µgml−1 Bi (III) ≡ 16 µgml−1 
moxifloxacin HCl.
Methods of Validation
Under the experimental conditions described above 
the optical characteristics such as Beer’s law limits, 
Sandell’s  sensitivity  and  molar  absorptivity39  were 
calculated for the proposed methods and the results 
are  summarized  in  (Table  1).  Regression  equations, 
intercepts, slopes and correlation coefficients for the 
calibration data are presented also in the same table 
while  standard  deviation,  relative  standard  deviation 
and standard error are summarized in (Tables 2 and 7).
Sensitivity
The detection limit (LOD) for the proposed methods 
were calculated using the following equation accord-
ing to definition40:
  LOD = 3s/k  (7)
where s is the standard deviation of replicate deter-
mination values under the same conditions as the 
sample in the absence of the analyte, and k is the 
sensitivity, namely the slope of the calibration graph. 
The detection limits obtained for the absorbance were 
found to be 0.0762, 0.21, 1.41, 1.423, 1.436 µg/ml 
for methods A, B, and C (Procedures 1, 2 and 3), 
respectively.
The limits of quantitation, LOQ, is defined as;
  LOQ = 10s/k  (8)
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Figure 6. Absorption spectra of Bi(III)- 88 µgml−l moxifloxacin ion pair 
(__) versus reagent blank (---).
Table 7. Determination of moxifloxacin HCl using method C (Procedures 1, 2 and 3).
Recovery %
procedure 1 procedure 2 procedure 3
98.79 98.51 99.46
100.93 100.27 98.44
99.81 99.32 100.12
100.79 100.85 100.25
99.09 100.71 101.07
99.94 100.41 100.41
 
 
Mean* ± standard deviation (P = 0.05)
100.46  
99.87  
99.96 ± 0.7593
99.99  
 
100.01 ± 0.8316
100.45  
99.03  
99.90 ± 0.860
n 8 7 8
relative standard deviation 0.7596 0.8315 0.861
Variance 0.5765 0.6915 0.7396
Standard error 0.268 0.314 0.304
note: *Mean of three different experiments.Development and validation of spectrophotometric, AAS, kinetic methods for determination of moxifloxacin
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According to this equation, the LOQs were found to be 
0.254, 0.6981, 4.676, 4.744, 4.788 µg/ml for   methods   
A, B, and C (Procedures 1, 2, and 3), respectively.
Accuracy and precision
In order to determine the accuracy and precision of 
the proposed methods, solutions containing 3 different 
concentrations of drug were prepared and analyzed in 
six replicate. The relative standard deviation as preci-
sion percentage relative error (Er %) as accuracy of the 
suggested methods were calculated at 95% confidence 
levels and can be considered satisfactory.   Precision 
was carried out by six determinations at three differ-
ent concentrations, the percentage relative error was 
calculated according to the following equation:
  Er % = [(found − added)/added] × 100
The inter- and intra-day precision and accuracy 
results are shown in (Table 8). The analytical results 
for accuracy and precision show that the proposed 
methods have good repeatability and reproducibility.
robustness and ruggedness
Robustness was examined by evaluating the influence 
of small variation of method variables including, con-
centration of analytical reagents, reaction time. In these 
experiments, one parameter was changed where as the 
others were kept unchanged, It was found that none 
of these variables significantly affect the method. This 
provided as indication for the reliability of the pro-
posed method during its routine application for analy-
sis of the investigated drug. Ruggedness was tested by 
applying the proposed methods to the assay of the drug 
using the same operational conditions but using two 
different instruments at two different laboratories and 
different elapsed time. Results obtained were found to 
be reproducible, as RSD did not exceed 2% (Table 9).
The % recoveries of the pure drug using the   proposed 
methods were compared with that given by the reference 
method4  are  illustrated  in  (Table  10). The    reference 
method recomonded is uv-spectrophotometric   procedure 
for determination of moxifloxacin hydrochloride using 
Table 9. results of evaluation of the ruggedness of the 
proposed spectrophotometric methods for determination 
of moxifloxacin HCl.
Method shimadzu  
UV-1800
shimadzu  
UV-260
Method A   99.94 ± 0.861 98.7466 ± 1.0103
Method B 101.01 ± 0.707    101.65 ± 1.225
Method C  
  Procedure 1
 
  99.96 ± 0.7593
 
   100.99 ± 1.2438
note: *recovery % ± SD.
Table 8. The inter-day precision and accuracy data for moxifloxacin HCl obtained by the proposed methods.
Method Added  
μgml-1
Intra-day Inter-day
Found ± se*  
μgml-1
precision  
RSD %
Accuracy  
R.M.E. %
Found ± se*  
μgml-1
precision  
RSD %
Accuracy 
R.M.E. %
A 1.2    1.18 ± 0.57 1.42 −1.05    1.20 ± 0.39 0.96 0.47
1.6    1.62 ± 0.11 0.26 1.5    1.61 ± 0.29 0.72 0.62
2.6    2.62 ± 0.17 0.43 0.96    2.62 ± 0.19 0.46 0.76
B 1.6    1.61 ± 0.17 0.42 0.79    1.60 ± 0.20 0.51 0.18
2.4    2.42 ± 0.13 0.31 1.08    2.42 ± 0.37 0.91 0.83
3.2    3.21 ± 0.26 0.64 0.59    3.22 ± 0.29 0.71 0.67
C
  Procedure 1 32 31.98 ± 0.46 1.15 −0.06 32.04 ± 0.49 1.20 0.12
64 64.44 ± 0.309 0.7528 0.682 64.46 ± 0.31 0.750 0.72
72 71.97 ± 0.342 0.839 −0.041 71.90 ± 0.360 0.884 −0.1388
  Procedure 2 24 23.64 ± 0.722 1.7967 −1.5 23.58 ± 0.620 1.546 −1.763
40 40.08 ± 0.501 1.2246 0.2 39.96 ± 0.579 1.421 −0.1
56 56.45 ± 0.296 0.719 0.803    56.4 ± 0.357 0.868 0.714
  Procedure 3 48 47.98 ± 0.452 1.107 −0.041 47.92 ± 0.485 1.189 −0.166
56 56.52 ± 0.468 1.137 0.928 56.34 ± 0.350 0.854 0.607
64 53.59 ± 0.315 0.777 −0.640 63.59 ± 0.315 0.777 −0.641
note: *Average of 6 determinations.Abdellaziz and hosny
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Table 10. Statistical data for the determination of moxifloxacin HCl using method (A–C) compared with reference method.
Item Reference  
method
Method A Method B Method c
procedure 1 procedure 2 procedure 3
Mean ± S.D.  
(P = 0.05)
101.03 ± 1.2 99.94 ± 0.8610 100.01 ± 0.7074 99.96 ± 0.7593 100.01 ± 0.8316 99.90 ± 0.860
n 9 5 5 8 7 8
r.S.D 1.276 0.8615 0.70737 0.7596 0.8315 0.861
V 1.664 0.7413 0.50041 0.5765 0.6915 0.7396
t – 1.67 (2.17) 0.5036 (2.17) 2.047 (2.131) 0.460 (2.145) 2.094 (2.131)
F – 2.24 (3.84) 3.325 (3.69) 2.886 (3.60) 2.406 (3.58) 2.249 (3.60)
note: *Values in parentheses indicate theoretical values of t and F at P = 0.05.
Table 11.   Application of standard addition technique for the determination of moxifloxacin HCl in pharmaceutical preparations 
using methods A and B.
Method A Method B
Taken (μgml-1) Added (μgml-1) Recovery % Taken (μgml-1) Added (μgml-1) Recovery %
0.8 – 97.42 0.8 – 101.63
0.8 98.48 1.2 99.08
1.6 98.16 1.6 98.81
2.4 99.11 2 100.80
3.2 100.65 2.8 100.58
5.2 98.75 3.2 100.42
Mean* ± SD 99.03 ± 0.9706 99.94 ± 0.9214
n 5 5
relative standard deviation 0.9801 0.9215
Variance 0.9421 0.848
note: *Mean of three different experiments.
Table 12. Application of standard addition technique for the determination of moxifloxacin HCl in pharmaceutical prepara-
tions using method C (Procedures 1, 2 and 3).
procedure 
1
procedure 2 procedure 3
Taken 
(μgml-1)
Added 
(μgml-1)
Recovery % Taken  
(μgml-1)
Added  
(μgml-1)
Recovery % Taken  
(μgml-1)
Added  
(μgml-1)
Recovery %
24 – 98.03 24 – 98.96 24 – 96.30
16 98.03 32 96.26 16 99.46
24 97.42 40 96.87 32 99.02
32 98.62 56 96.48 40 101.13
48 98.56 64 98.27 48 100.34
56 98.87
72 99.11
Mean* ± SD 98.44 ± 0.61 96.97 ± 0.90 99.99 ± 0.9387
n 6 4 4
SD 0.6146 0.902 0.9387
rSD 0.6243 0.930 0.9387
V 0.3777 0.813 0.88115
note: *Mean of three different experiments.Development and validation of spectrophotometric, AAS, kinetic methods for determination of moxifloxacin
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0.1 N HCl. The validity of the proposed methods was 
evaluated by statistical   analysis41 between the results 
obtained and that of reference method. Regarding the 
calculated  student’s,  t-test  and  variance  ratio  F-test, 
there is no significant difference between the proposed 
methods and the reference one.
Application
The proposed methods were successfully applied to 
determine moxifloxacin HCl in its commercial   tablets 
using standard addition technique (Tables 11 and 12).
conclusion
The proposed methods described in this paper are 
simple, economic, sensitive, don’t require expensive 
reagents and sophisticated instruments. These meth-
ods are applicable for routine analysis of the studied 
drug in raw materials and pharmaceutical formula-
tions  over  wide  concentration  range  without  inter-
ference from common excipients. The methods can 
use both spectrophotometric and (AAS) techniques 
for the final measurement step, moreover, they also 
have the advantages that no extraction is needed to 
separate the ion- pair formed and so avoiding the haz-
ards of the organic solvents being simpler and more 
convenient.  The  statistical  parameters  indicate  the 
reproducibility and accuracy of the methods.
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